Authorities in Europe just approved the first non-pharma treatment for attention deficit hyperactivity disorder (ADHD). The Monarch eTNS system from NeuroSigma, a Los Angeles, CA firm, electrically stimulates the trigeminal nerve non-invasively. It has been already in use in the EU for controlling epilepsy and depression, but the device is still in an investigational stage in the U.S.
The Monarch is being studied right now at UCLA involving 90 subjects in a double-blind trial for ADHD, so we might be seeing FDA approval in the not too distant future.
Flashbacks: NeuroSigma’s Monarch eTNS System for Epilepsy, Depression Cleared in Europe…; Trigeminal Nerve Stimulation for Epilepsy Management Proving Itself in Latest Trial…; Trigeminal Stimulation as an Epilepsy Treatment…
Product page: Monarch eTNS Therapy…
Source: NeuroSigma…